|
ATE400252T1
(de)
|
1999-02-10 |
2008-07-15 |
Pfizer Prod Inc |
Pharmazeutische feste dispersionen
|
|
US6440959B1
(en)
*
|
1999-04-21 |
2002-08-27 |
Hoffman-La Roche Inc. |
Pyrazolobenzodiazepines
|
|
PE20010659A1
(es)
*
|
1999-10-01 |
2001-06-20 |
Hoffmann La Roche |
Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
|
|
US6313143B1
(en)
*
|
1999-12-16 |
2001-11-06 |
Hoffmann-La Roche Inc. |
Substituted pyrroles
|
|
DK1301221T3
(da)
*
|
2000-05-16 |
2006-07-03 |
Ortho Mcneil Pharm Inc |
Fremgangsmåde til overtrækning af medicinske artikler ved anvendelse af superkritisk carbondioxid
|
|
US6469179B1
(en)
|
2000-10-03 |
2002-10-22 |
Hoffmann-La Roche Inc. |
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
|
|
US6482847B2
(en)
*
|
2000-10-03 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
|
|
US6951656B2
(en)
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
|
US7193084B2
(en)
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
|
US6884436B2
(en)
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
|
US20050048126A1
(en)
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
|
US8067032B2
(en)
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
|
US6977085B2
(en)
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
|
US7037528B2
(en)
|
2000-12-22 |
2006-05-02 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
|
US6548531B2
(en)
|
2001-02-09 |
2003-04-15 |
Hoffmann-La Roche Inc. |
Method for cancer therapy
|
|
US6716845B2
(en)
|
2001-03-30 |
2004-04-06 |
Hoffmann-La Roche Inc. |
Barbituric acid derivatives
|
|
ATE392203T1
(de)
*
|
2001-05-30 |
2008-05-15 |
Csir |
Verfahren zur verkapselung eines wirkstoffs
|
|
US20030044514A1
(en)
*
|
2001-06-13 |
2003-03-06 |
Richard Robert E. |
Using supercritical fluids to infuse therapeutic on a medical device
|
|
WO2002102373A1
(en)
*
|
2001-06-15 |
2002-12-27 |
F. Hoffmann-La Roche Ag |
Method for administration of cancer therapeutic
|
|
ATE480226T1
(de)
|
2001-06-22 |
2010-09-15 |
Bend Res Inc |
Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
|
|
MXPA03011784A
(es)
|
2001-06-22 |
2004-04-02 |
Pfizer Prod Inc |
Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
|
|
US20060003012A9
(en)
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
|
CN1558755A
(zh)
|
2001-09-26 |
2004-12-29 |
���ع��ʹ�˾ |
通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
|
|
US7112340B2
(en)
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
|
US20030139373A1
(en)
*
|
2001-11-20 |
2003-07-24 |
Breimer Lars Holger |
Method for cancer therapy
|
|
PL372247A1
(en)
*
|
2002-02-01 |
2005-07-11 |
Pfizer Products Inc. |
Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
|
|
RU2005103625A
(ru)
|
2002-08-12 |
2005-08-20 |
Пфайзер Продактс Инк. (Us) |
Фармацевтические композиции полуупорядоченных лекарств и полимеров
|
|
DE10351087A1
(de)
*
|
2003-10-31 |
2005-05-25 |
Bayer Technology Services Gmbh |
Feste Wirkstoff-Formulierung
|
|
DE602004031144D1
(de)
|
2003-11-14 |
2011-03-03 |
Ajinomoto Kk |
Feste dispersion oder medizinisches festes dispersionspräparat eines phenylalanin-derivats
|
|
EP3216449A1
(en)
*
|
2003-11-14 |
2017-09-13 |
EA Pharma Co., Ltd. |
Oral administration preparation of phenylalanine derivatives
|
|
RU2411043C2
(ru)
*
|
2004-04-01 |
2011-02-10 |
Юниверсите Де Льеж |
Фармацевтические композиции пиримидин-2,4,6-трионов
|
|
AR049915A1
(es)
*
|
2004-06-14 |
2006-09-13 |
Anacor Pharmaceuticals Inc |
Compuestos con contenido de boro y metodos de uso de los mismos
|
|
WO2006062980A2
(en)
*
|
2004-12-07 |
2006-06-15 |
Nektar Therapeutics |
Stable non-crystalline formulation comprising tiagabine
|
|
CN101115469A
(zh)
*
|
2004-12-28 |
2008-01-30 |
卫材R&D管理有限公司 |
速崩片及其制造方法
|
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
|
US9040558B2
(en)
|
2004-12-31 |
2015-05-26 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
|
RU2411045C2
(ru)
*
|
2005-01-27 |
2011-02-10 |
Институт Нефтехимического Синтеза Имени А.В. Топчиева Ран |
Гидрофильные биологически совместимые адгезивные композиции и их применение
|
|
EP1690528A1
(de)
*
|
2005-02-11 |
2006-08-16 |
Abbott GmbH & Co. KG |
Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
|
|
CA2608952A1
(en)
*
|
2005-05-19 |
2006-11-23 |
Dwayne Thomas Friesen |
Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
|
|
EP1767194A1
(de)
*
|
2005-06-09 |
2007-03-28 |
Helm AG |
Verfahren zur Herstellung von Adsorbaten des Drospirenons
|
|
MY153898A
(en)
*
|
2005-06-22 |
2015-04-15 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
US20080031944A1
(en)
*
|
2006-08-04 |
2008-02-07 |
Cima Labs Inc. |
Stabilization of lorazepam
|
|
PE20080422A1
(es)
*
|
2006-08-10 |
2008-04-28 |
Cipla Ltd |
Composicion solida antirretroviral de administracion oral
|
|
US20080107725A1
(en)
*
|
2006-10-13 |
2008-05-08 |
Albano Antonio A |
Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
WO2008079909A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
|
PE20121126A1
(es)
*
|
2006-12-21 |
2012-08-24 |
Plexxikon Inc |
Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
|
|
JPWO2008081829A1
(ja)
*
|
2006-12-27 |
2010-04-30 |
アステラス製薬株式会社 |
難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe
|
|
CA2686756A1
(en)
*
|
2007-05-11 |
2008-11-20 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions for poorly soluble drugs
|
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
|
EP1997479A1
(en)
*
|
2007-05-31 |
2008-12-03 |
Helm AG |
Stabilized amorphous candesartan cilexetil compositions for oral administration
|
|
MX2010000617A
(es)
|
2007-07-17 |
2010-05-17 |
Plexxikon Inc |
Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
|
|
AU2008312321A1
(en)
*
|
2007-10-19 |
2009-04-23 |
Purdue Research Foundation |
Solid formulations of crystalline compounds
|
|
US7794750B2
(en)
*
|
2008-06-20 |
2010-09-14 |
Mutual Pharmaceutical Company, Inc. |
Controlled-release formulations, method of manufacture, and use thereof
|
|
US8632805B2
(en)
*
|
2008-06-20 |
2014-01-21 |
Mutual Pharmaceutical Company, Inc. |
Controlled-release formulations, method of manufacture, and use thereof
|
|
WO2010044842A1
(en)
*
|
2008-10-16 |
2010-04-22 |
University Of Tennessee Research Foundation |
Tamper resistant oral dosage forms containing an embolizing agent
|
|
KR20100073454A
(ko)
*
|
2008-12-23 |
2010-07-01 |
국립암센터 |
트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
|
|
MY172424A
(en)
*
|
2009-04-03 |
2019-11-25 |
Hoffmann La Roche |
Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
|
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
|
JP2013510166A
(ja)
|
2009-11-06 |
2013-03-21 |
プレキシコン インコーポレーテッド |
キナーゼ調節のための化合物、方法およびその適用
|
|
CN103153306A
(zh)
*
|
2010-05-31 |
2013-06-12 |
安斯泰来制药有限公司 |
三唑化合物的固体分散体
|
|
EA028821B9
(ru)
|
2011-02-07 |
2018-10-31 |
Плексксикон, Инк. |
Соединения и способы для модуляции киназ, а также показания к их применению
|
|
BR112013021030A2
(pt)
|
2011-02-17 |
2016-10-11 |
Hoffmann La Roche |
processo para cristalização controlada de um ingrediente farmacêutico ativo a partir de estado líquido super-refrigerado por extrusão por fusão a quente
|
|
AR085279A1
(es)
|
2011-02-21 |
2013-09-18 |
Plexxikon Inc |
Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
|
|
PE20150928A1
(es)
|
2011-06-20 |
2015-06-26 |
Lundbeck & Co As H |
1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
|
|
EP2744803A2
(en)
|
2011-08-18 |
2014-06-25 |
Dr. Reddy's Laboratories Ltd. |
Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
|
|
WO2013037396A1
(en)
*
|
2011-09-12 |
2013-03-21 |
Bioneer A/S |
Solution of polymer in api for a solid dosage form
|
|
MX352074B
(es)
|
2011-09-27 |
2017-11-08 |
Dr Reddys Laboratories Ltd |
Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
|
|
PT2765990T
(pt)
|
2011-10-14 |
2017-11-14 |
Array Biopharma Inc |
Dispersão sólida
|
|
NZ741615A
(en)
|
2012-03-23 |
2019-10-25 |
Array Biopharma Inc |
Treatment of brain cancer
|
|
US20140128431A1
(en)
|
2012-04-03 |
2014-05-08 |
Hoffmann-Laroche Inc. |
Pharmaceutical composition with improved bioavailability, safety and tolerability
|
|
EP2649989B1
(en)
|
2012-04-13 |
2017-10-18 |
King Saud University |
Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
JO3339B1
(ar)
*
|
2012-09-11 |
2019-03-13 |
Shanghai Inst Pharmaceutical Ind |
شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
|
|
MX2015006223A
(es)
|
2012-11-19 |
2015-09-25 |
Reddys Lab Ltd Dr |
Composiciones farmaceuticas de inhibidores cetp.
|
|
EP2934486A2
(en)
|
2012-12-20 |
2015-10-28 |
Kashiv Pharma, LLC |
Orally disintegrating tablet formulation for enhanced bioavailability
|
|
NZ708272A
(en)
|
2013-01-22 |
2020-07-31 |
Hoffmann La Roche |
Pharmaceutical composition with improved bioavailability
|
|
TWI615157B
(zh)
|
2013-02-06 |
2018-02-21 |
大塚製藥股份有限公司 |
包括不定形西洛他唑的固體分散劑
|
|
WO2015038376A1
(en)
*
|
2013-09-11 |
2015-03-19 |
3M Innovative Properties Company |
Coating compositions, dental structures thereof and methods for generating contrast
|
|
US20160303102A1
(en)
*
|
2013-12-05 |
2016-10-20 |
Alrise Biosystems Gmbh |
Process for the production of drug formulations for oral administration
|
|
PT107846B
(pt)
*
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
BR112017025739A2
(pt)
*
|
2015-05-29 |
2018-08-07 |
Sun Pharmaceutical Ind Ltd |
composição farmacêutica oral de isotretinoína que tem biodisponibilidade aumentada, processo para preparar a mesma e método de tratamento
|
|
SMT202500245T1
(it)
*
|
2016-12-13 |
2025-07-22 |
Transthera Sciences Nanjing Inc |
Composto inibitore multi-chinasi, forma cristallina e suo utilizzo
|
|
WO2018201016A1
(en)
|
2017-04-28 |
2018-11-01 |
Cascadian Therapeutics, Inc. |
Treatment of her2 positive cancers
|
|
KR102082775B1
(ko)
*
|
2017-05-02 |
2020-02-28 |
주식회사 삼양바이오팜 |
수용해도 및 생체이용율이 개선된 조성물
|
|
RU2725879C2
(ru)
*
|
2018-07-26 |
2020-07-07 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации |
Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
|
|
WO2020114853A1
(en)
|
2018-12-03 |
2020-06-11 |
H. Lundbeck A/S |
Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
|
|
WO2021150981A1
(en)
*
|
2020-01-24 |
2021-07-29 |
Nanocopoeia, Llc |
Amorphous solid dispersions of dasatinib and uses thereof
|
|
WO2021155254A1
(en)
|
2020-01-31 |
2021-08-05 |
Nanocopoeia, Llc |
Amorphous nilotinib microparticles and uses thereof
|
|
JP7705715B2
(ja)
|
2020-03-03 |
2025-07-10 |
デクセリアルズ株式会社 |
画像表示装置の製造方法
|
|
CA3181361A1
(en)
|
2020-04-30 |
2021-11-04 |
Nanocopoeia, Llc |
Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
|
|
US11980619B2
(en)
|
2021-07-28 |
2024-05-14 |
Nanocopoeia, Llc |
Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
|